Bristol Myers Squibb (CELG-RI) Shareholder's Equity Growth (3y) (2012 - 2026)

Bristol Myers Squibb (CELG-RI) Shareholder's Equity Growth (3y) (2012 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 309.61%
Dec 31, 2025 154.17%
Sep 30, 2025 188.92%
Jun 30, 2025 26.02%
Mar 31, 2025 65.00%
Dec 31, 2024 -14.45%
Sep 30, 2024 -81.25%
Jun 30, 2024 0.00%
Mar 31, 2024 -44.17%
Dec 31, 2023 5.62%
Sep 30, 2023 -17.49%
Jun 30, 2023 -41.07%
Mar 31, 2023 -81.99%
Dec 31, 2022 -26.60%
Sep 30, 2022 -26.98%
Jun 30, 2022 -61.15%
Mar 31, 2022 -83.81%
Dec 31, 2021 528.38%
Sep 30, 2021 47.69%
Jun 30, 2021 -71.35%